Visiongain Publishes Point of Care Diagnostics Market Report 2021-2031
02 March 2021
Visiongain has published a new report Point of Care Diagnostics Market Report 2021-2031: Forecast by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Haematology Testing, Drugs-of-abuse Testing, Faecal Occult Testing, Other POC Products), by Mode (Prescription-based, OTC), by End User (Clinics, Hospitals, Home Care Setting, Other End Users) AND Regional and Leading National Market Analysis PLUS Analysis of Leading POC Companies AND COVID-19 Recovery Scenarios.
The global point of care diagnostics market was valued at $xx million in 2020, and is projected to reach $xx million in 2031, registering a CAGR of x% from 2021 to 2031. Point-of-care diagnostics is as an investigation undertaken at the time of the consultation with instantaneous availability of results to make speedy and informed decisions in relation to patient care. It allows physicians and medical staff to accurately achieve real-time, lab-quality diagnostic results within minutes rather than hours. Recent years have seen significant advances in point-of-care diagnostics test and devices.
Rise in prevalence of target condition has led to increase in adoption of PoC diagnostic in clinics, hospitals and even in homecare settings. Diabetes is a severe, long-term condition which can have a major impact on the lives and well-being of individuals, and families worldwide. According to International Diabetes Federation (IDF), in 2019, approximately 463 million adults were living with diabetes in the world which is further anticipated to rise to 700 million by 2045. China accounted for the largest number of people with diabetes followed by India which had the second highest diabetic population. The point of care diagnostics for glucose monitoring was the highest contributor to the global market and is anticipated to dominate the market during the forecast period 2021-2031.
Moreover, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Whereas, cancer is the second prominent cause of death globally, with an estimated 9.6 million deaths in a year. OTC or prescription based PoC tests assists in regular monitoring of blood glucose, to detect high troponin values for CVDs, and in early detection and screening of cancer biomarkers which further enables doctors to design an effective therapy and to figure out the necessity to admit the individual to the hospital. In 2020, the point of care diagnostics market for OTC was the highest contributor to the global market.
Other factors such as high prevalence of infectious diseases namely HIV, tuberculosis, malaria, Ebola, influenza, etc. in both developed and developing countries, is also expected to drive the adoption of PoC testing worldwide. Moreover the ongoing pandemic of Covid-19 has put the world to standstill. According to WHO, there have been 107,423,526 confirmed cases of COVID-19, including 2,360,280 deaths as of February 2021. The US recorded more than 27.4 million Covid-19 cases followed by India and Brazil with 10.9 million & 9.7 million cases respectively as of February 2021. This has led to a high surge in demand for PoC diagnostics in hospitals.
The Visiongain report analyst commented that “It is essential for the point of care diagnostic device manufacturers to focus on developing more PoC devices that can run multiple analyses on single device. These devices simultaneously measure multiple analyses on the same cartridge also known as multiplexing. Multiplex PoC tests has numerous advantages over widely adopted singleplex test such as greater output per sample, higher throughput and increased efficiency at lower costs. These advantages of multiplex devices over singleplex devices will help in gaining more resolute and detailed diagnostics and facilitate personalized medicine for patient suffering from various conditions.”
In 2019, The North America point of care diagnostics market was the highest contributor to the global market. This is due to the growing prevalence of lifestyle diseases, and target conditions, supported by advance medical technology and increasing number of product approvals in the region. Whereas, Asia-Pacific point of care diagnostic market is anticipated to growth at the highest CAGR during the forecast period. This is attributed to high prevalence of infectious diseases, and large number of diabetic patients leading to rise in adoption of PoC tests in countries such as China and India. Also increase in government support indicates a favourable approval environment globally and which will encourage key manufacturers to focus and contribute to innovation thereby driving the market growth.
However, despite the high demand for PoC test and PoC diagnostic devices, manufacturers are facing several regulatory barriers due to multi-layered regulations set by the FDA and laboratory regulations under CLIA for the premarket approval of PoC testing kits which might pose a threat to the market growth.
To gain additional share in the point of care diagnostic market, key manufacturers are adopting several strategies and development such as new product launch/approval, acquisition, partnership, collaboration, expansion and technology development. For instance, In December 2020, Beckman Coulter a Danaher acquired company, launched the new Access SARS-CoV-2 Antigen assay capable of processing up to 200 samples per hour, enabling high throughput screening in just 30 minutes. In November 2020, Becton, Dickinson and Company launched its rapid point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System. In October 2020, Siemens Healthineers launched rapid antigen test for the detection of SARS-CoV-2 in 15 minutes which helps in isolating covid-19 +ve patients sooner and avoid the spread. In May 2020, Chembio Diagnostic made an agreement with Thermo Fisher Scientific (US) to expand its commercial footprint in the US by strengthening the distribution channel for Chembio’s DPP COVID-19 system across the US. Key players profiled in the report include Abbott Laboratories, Roche, Quidel, AccuBiotech, Johnson & Johnson, Becton, Dickinson, and Company, Danaher Corporation, PTS Diagnostics, Trinity Biotech, Siemens Healthineers Group Chembio Diagnostic Systems, Instrumentation Laboratory, Nova Biomedical, Sekisui Diagnostics and Fluxergy.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.